AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	364.93M
Revenue (ttm)	236.25M
Net Income (ttm)	17.45M
Shares Out	104.87M
EPS (ttm)	0.16
PE Ratio	21.51
Forward PE	21.97
Dividend	0.02 (0.52%)
Ex-Dividend Date	Jun 18, 2025

Volume	2,149
Average Volume	8,458
Open	3.550
Previous Close	3.550
Day's Range	3.480 - 3.550
52-Week Range	2.410 - 3.750
Beta	0.37
RSI	49.69
Earnings Date	Feb 18, 2026

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2024, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.